Efficacy of galcanezumab in patients with episodic migraine and a history of preventive treatment failure: results from two global randomized clinical trials.
D D RuffJ H FordA Tockhorn-HeidenreichV L StaufferSriram GovindanS K AuroraG M TerwindtP J GoadsbyPublished in: European journal of neurology (2019)
In patients with episodic migraine treated with galcanezumab, those with ≥1 or ≥2 prior preventive failures had significantly larger improvements, versus placebo, in efficacy outcomes. Similar results were observed in patients with no prior failure, with a larger placebo response.